This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer (ZBH) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent positive developments.
Edwards Lifesciences (EW) Recalls PASCAL's Guide Sheath
by Zacks Equity Research
Edwards Lifesciences (EW) issues a product recall for its guide sheath based on report from its urgent field safety notice.
InMode (INMD) Looks Good: Stock Adds 5.6% in Session
by Zacks Equity Research
InMode (INMD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes
by Zacks Equity Research
QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.
Amedisys Partners With nVoq to Improve Clinician Experience
by Zacks Equity Research
Amedisys (AMED) aims to enhance clinician workflow by integrating nVoq's technology platform into its home health business.
New Strong Buy Stocks for November 18th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Haemonetics (HAE) Grows on New Products, Robust Plasma Sales
by Zacks Equity Research
Haemonetics (HAE) witnesses a steady uptick in Plasma franchise, fueled by favorable price, volume and mix.
Insulet (PODD) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Insulet (PODD) has been gaining from several positive developments recently.
Here's Why You Should Hold on to CVS Health (CVS) For Now
by Zacks Equity Research
Investors can still hold on to CVS Health (CVS) stock, thanks to its solid prospects.
CVS Health's New Plans With Aetna May Improve Health Outcomes
by Zacks Equity Research
CVS Health's (CVS) Health Care Benefits segment develops Medicare program with Aetna.
Syneos Health Collaborates with AiCure for Patient Engagement
by Zacks Equity Research
Syneos Health (SYNH) aims to optimize patient engagement and trial success by partnering with AiCure.
Here's Why You Should Add NuVasive (NUVA) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about NuVasive's (NUVA) stellar performance.
Insulet Rides on Omnipod's Wider Market Reach, New Products
by Zacks Equity Research
Insulet (PODD) achieves several milestones with respect to strengthening Omnipod's market access.
Hologic's (HOLX) 3DQuorum Imaging Technology Gets FDA Nod
by Zacks Equity Research
The regulatory clearance is likely to boost Hologic's (HOLX) Breast and Skeletal Health Solutions business segment.
Globus Medical's U.S. Spine Arm Grows, Product Launches Aid
by Zacks Equity Research
Globus Medical (GMED) is on course to commercially market ExcelsiusGPS platform and launch its spine deformity solution in early fourth quarter.
Hologic's Aptima Genitalium Assay Gets Clinically Verified
by Zacks Equity Research
This study result is expected to be a major stride forward in Hologic's (HOLX) commitment toward strengthening its Diagnostic Solutions business.
Medtronic (MDT) Releases Positive Study Results on Pacemaker
by Zacks Equity Research
Medtronic (MDT) presents favorable results from study on leadless pacemaker, indicating potential for improving cardiac functions in patients having blockages.
CVS Health's Aetna Prospects Solid, Omnicare Sluggish
by Zacks Equity Research
CVS Health's (CVS) strong Pharmacy Services segment sales gain traction from growth in specialty services.
Zimmer (ZBH) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Zimmer (ZBH) is likely to maintain the current high on a number of favorable factors.
Myriad Genetics Presents New Test Data in Autoimmune Segment
by Zacks Equity Research
Myriad Genetics (MYGN) presents key findings related to Vectra test from its autoimmune segment.
Haemonetics (HAE) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.
Haemonetics (HAE) Beats on Q2 Earnings, Raises '20 EPS View
by Zacks Equity Research
Haemonetics (HAE) delivers robust fiscal second-quarter revenues, fueled by strong performances in Plasma and Hospital segments.
Haemonetics (HAE) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 20.83% and 1.12%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Chemed (CHE) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed's (CHE) performance.